Nanologica AB (NICA) AI Stock Analysis

• Market Cap: kr111.77M
• Dividend Yield: N/A
• Average Volume (3M): 482.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 230.57%
• EPS Growth: 46.64%
• Country: SE
• Employees: 16
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 88,357,230
• 10 Day Avg. Volume: 271,625
• 30 Day Avg. Volume: 482,001
• PEG Ratio: -0.08
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Nanologica AB's stock score is primarily impacted by its financial performance, which is challenged by low profitability and negative cash flow. Technical analysis shows mixed momentum, with some bullish signals but overall downward pressure. Valuation is hindered by a negative P/E ratio and the absence of dividend yield, reflecting concerns over ongoing losses and profitability.

Nanologica AB Business Overview & Revenue Model

Company Description

Nanologica AB (NICA) is a Swedish company specializing in the development and manufacturing of nanoporous silica particles. These particles have various applications, particularly in the pharmaceutical and biopharmaceutical sectors, where they are used for drug formulation and delivery. The company's core products include silica for chromatography and drug delivery systems, leveraging its proprietary technology to enhance drug solubility and bioavailability.

How the Company Makes Money

Nanologica AB generates revenue primarily through the sale of its nanoporous silica particles, which are utilized in pharmaceuticals for drug formulation and delivery. The company's business model includes selling these materials directly to pharmaceutical and biopharmaceutical companies. Additionally, Nanologica may engage in partnerships or collaborations with other firms to further advance its technology and applications, contributing to its earnings. Revenue streams are likely influenced by the demand for more efficient drug delivery solutions and the company's ability to innovate and maintain proprietary technological advantages.

Nanologica AB Financial Statement Overview

Summary

Nanologica AB faces challenges with profitability and cash flow, despite some revenue growth. The balance sheet indicates moderate leverage, but financial stability is threatened by periodic negative equity. The company must focus on enhancing revenue stability, cost management, and reducing debt to improve its financial health and support long-term growth.

Income Statement

Nanologica AB has shown significant volatility in revenue, with fluctuating growth rates. The TTM (Trailing-Twelve-Months) revenue growth indicates improvement, but the company consistently reports negative net profit margins due to high operating costs, reflected in the negative EBIT and EBITDA margins. The company needs to stabilize its revenue growth and manage costs to improve profitability.

Balance Sheet

The company's balance sheet reveals a moderate debt-to-equity ratio with a relatively stable equity over the years. However, the company has negative stockholders' equity in some periods, indicating potential financial instability. The equity ratio is low, highlighting a reliance on liabilities to finance assets. Improving equity and reducing liabilities could strengthen the financial position.

Cash Flow

Nanologica AB experiences negative free cash flow, indicating challenges in generating sufficient cash from operations. Although the operating cash flow to net income ratio is relatively consistent, the company shows significant financing cash flow, suggesting reliance on external funding. Effective cash flow management is essential for improving liquidity and reducing dependence on external financing.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
20.25M	14.54M	1.44M	1.55M	12.91M	16.14M
	Gross Profit
616.00K	4.29M	-76.00K	3.23M	4.92M	14.99M
	EBIT
-53.17M	-59.26M	-69.96M	-50.14M	-39.03M	-20.11M
	EBITDA
-37.19M	-45.17M	-62.12M	-38.36M	-31.13M	-13.05M
	Net Income Common Stockholders
-59.03M	-65.63M	-75.16M	-55.09M	-50.13M	-24.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
28.35M	48.43M	10.05M	70.32M	11.70M	67.98M
	Total Assets
125.09M	143.10M	77.43M	154.51M	98.32M	146.34M
	Total Debt
7.24M	50.94M	666.00K	4.69M	9.79M	12.96M
	Net Debt
-21.10M	2.51M	-9.39M	-65.63M	-1.20M	-53.40M
	Total Liabilities
61.15M	68.99M	79.33M	81.36M	46.72M	53.38M
	Stockholders Equity
63.94M	74.11M	-1.90M	73.16M	51.60M	92.97M
Cash Flow		Free Cash Flow
-90.17M	-81.48M	-56.83M	-53.78M	-53.74M	-49.86M
	Operating Cash Flow
-89.91M	-80.73M	-35.85M	-45.22M	-46.49M	-43.34M
	Investing Cash Flow
-256.00K	-742.00K	-20.35M	-7.14M	-7.25M	-6.52M
	Financing Cash Flow
89.12M	120.23M	-4.09M	111.70M	-1.64M	115.05M

Nanologica AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NICA, the sentiment is Neutral. The current price of 1.26 is above the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.28, and below the 200-day MA of 2.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 54.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NICA.

Nanologica AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
NICA	44 Neutral	kr111.77M	―	-151.10%	―	230.57%	46.64%
SPAGO	38 Underperform	€67.38M	―	-105.78%	―	58.72%	70.69%
BIOSGN	34 Underperform	kr107.78M	―	-82.34%	―	―	35.61%
ACTI	32 Underperform	€153.52M	―	-186.40%	―	―	24.47%